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1. Introduction 
Human onchocerciasis is a public health problem and an obstacle to socioeconomic 
development in endemic countries of Africa, Arabian Peninsula and South America 
(WHO, 1995). The community-directed treatment with ivermectin (CDTI) is the main 
strategy adopted by the African Programme for Onchocerciasis control (APOC). Severe 
adverse events with encephalopathy (SAEs) have been associated with mass treatment 
with ivermectin (Mectizan) in areas where Loa loa and onchocerciasis are co-endemic 
(Duke, 2003; Twum-Danso, 2003). This has caused wide spread concern on the 
sustainability of CDTI (Amazigo et al., 2002; Addiss et al., 2003). The most important risk 
encountered in distributing ivermectin for the control of onchocerciasis in areas where Loa 
loa is co-endemic is the development of an encephalopathic syndrome. The pathogenesis 
of Loa loa encephalopathy is not fully understood, but the primary determinant is the level 
of Loa loa microfilaraemia (Gardon et al., 1997; Boussinesq et al., 1998; Gardon et al., 1999; 
Boussinesq et al., 2001) and the inflammatory response to the dying worms (McGarry et 
al., 2003).  
Post ivermectin treatment encephalopathies with fatal outcome have repeatedly been the 
subject of clinical and operational investigations. Investigations have targeted aspects of 
implementing mass drug administration, monitoring and referral of early signs of SAE, 
improved clinical management in the communities and health facilities.Research for 
primary prevention have also witnessed the development of operational tools, aimed at 
identifying high risk communities, using in the communities and health Normalized-
Difference Vegetation Index (NDVI) and rapid assessment methods (Diggle et al., 2007). For 
the later purpose, RAPLOA is used to identify communities at risk of SAEs. The objective of 
the present chapter is to provide an updated review of gathered evidence on the 
pathophysiology of Loa loa mediated encephalopathy and the existing methods for its 
prevention and case management at the community level. 
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2. Epidemiology 
Onchocerciasis, also known as river blindness, is caused by a filarial nematode, Onchocerca 
volvulus. The adult worms lives in subcutaneous nodules within surface muscles, mainly 
around the pericostal and the iliac crest.  
There are two mains subtypes of Onchocerca volvulus, namely the forest and savanah. In the 
savanal infections, the nodules are mainly located on the upper part of the body, including 
the trunk, upper limbs and head. Ocular involvement is frequent. In the forest infections, 
nodules are found primarily on the lower limbs and iliac crest. Cutaneous alterations are the 
main manifestations of the disase. 
The worm is transmitted through the bite of female blackflies of the genus Simulium, which 
bite during the day. The fly breeds in rapidly flowing rivers and streams. 
Onchocerciasis is endemic in most countries in sub-saharan Africa. Isolated endemic foci are 
also present in the Arabian Peninsula (Yemen) and in the Americas (Brazil, Colombia, 
Ecuador, Guatemala, southern Mexico, and Venezuela). An estimated 17 million people are 
infected worldwide. 
The distribution of the disease has been substantially narrowed with the successful 
implementation of the Onchocerciasis Control Programme in West Africa (OPC) and the 
African Programme for Onchocerciasis Control (APOC). OPC used aerial spray of 
insecticides for the control of onchocerciasis fly vector from 1974 to 2000 when the 
programme closed down, after reaching its goal. APOC began its activities in 1995. Its main 
strategy is the annual or biannual distribution of ivermectin, a safe and effective drug that 
was licensed for human use in 1987. APOC is a partnership involving international donors, 
the private sector including pharmaceutical companies, Non-governmental Organizations 
and communities. The delineation of roles and responsibilities within the partnership has 
been the subject of extended literature and consultative statutory meetings regularly hold to 
monitor progress towards the control and elimination of the disease. Unfortunately, 
progress in the control of onchocerciasis in APOC countries met with difficulties as the 
programme progressed towards central Africa where the level of endemicity of Loa loa is 
highest. Loa loa is a filarial worm that inhabits the subcutaneous tissue of humans. The 
disease is transmitted from one host to the other through the bite of the Chrysops fly. The 
adult breeds in marshy forested habitats. In areas that are co-endemic for both 
onchocerciasis and loiasis, the mass administration of ivermectin for treatment of 
onchocerciasis sometimes leads to the occurrence of Severe Adverse Events (SAE) consisting 
of a potentially lethal encephalopathy. 
Short-term travelers to endemic areas are at low risk for this infection. Travelers who visit 
endemic areas for extended periods of time (generally >3 months) and live or work near 
black fly habitats are at risk for Loa loa infections. 
Infection with O. volvulus results in skin lesions, including a highly pruritic, papular 
dermatitis; subcutaneous nodules; lymphadenitis. Ocular lesions occur in endemic countries 
and can progress to visual loss and blindness. Historically, the term river blindness was 
coined from the blindness that occurred along streams that were onchocerciasis 
transmission sites. Symptoms in travelers are primarily dermatologic and may occur months 
to years after departure from endemic areas. Immigrants from endemic areas may present 
with skin or ocular disease. 
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Onchocerciasis is diagnosed by finding the microfilariae in punch biopsy, adult worms in 
histologic sections of excised nodules or characteristic eye lesions. Serologic testing is most 
useful for detecting infection in specific groups, such as expatriates with a brief exposure 
history, when microfilariae are not identifiable. It is equally expected that serological tests 
and molecular markers will get into wide use as interventions move towards disease 
elimination goals. 
Ivermectin (150–200 µg/kg orally, once or twice per year) is the drug of choice for 
onchocerciasis. Repeated annual or semiannual doses may be required. The drug kills the 
microfilariae but not the adult worms, which can live for 15-17 years. Antibiotic trials with 
doxycycline (100 mg orally per day) directed against Wolbachia, an endosymbiont of O. 
volvulus, have demonstrated a decrease in onchocercal microfiladermia with 6 weeks of 
therapy. Therefore, some experts recommend treating patients with 1 dose of ivermectin 
followed by 6 weeks of doxycycline. Several health workers however advocated against the 
wide use of antibiotics in communities as it could foster specific or cross another constrain is 
the problematic compliance with the numerous doses treatment regimen. 
Subcutaneous nodules can be excised if their anatomic location allows it to be done safely.  
No vaccine or drug to prevent Onchocerca infection is available. Protective measures include 
avoiding blackfly habitats and the use of personal protection measures against biting insects. 
 
Fig. 1. Life cycle of the Loa loa parasite, involving the human host and the Chrysops vector. 
Reprinted from the CDC webpage. 
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3. Particularities of the health infrastructure in onchocerciasis and loiasis 
endemic areas  
Populations most affected by onchocerciasis and loiasis live in remote areas of endemic 
countries where they are poor and underserved by the health system. In fact, despite the 
Alma Ata Declaration on Primary Health Care (PHC) of 1978 - a system envisaged for 
improving access to health interventions – equity and access to essential health services 
remain sub-optimal in sub-Saharan Africa, especially in rural areas. The international 
community have recognized the potential of PHC (WHO, 2008). There are attempts to its 
revitalization and PHC has been placed high on the agenda of several international fora 
(African Review of the Implementation of PHC in Ouagadougou).  
Recent efforts by the World Health Organisation (WHO, 2006) emphasized that a significant 
proportion of the national health budget should focus on interventions linked to the MDGs, 
targeting those most in need. Unfortunately, African health systems continue to be weak, 
with fragmented interventions. Health services lack effective mechanisms for making any 
real impact on the high burden of infectious diseases. Health systems in onchocerciasis 
endemic countries (mainly in Africa) lack sustainable frameworks to involve partners from 
other development sectors. However, a functioning health system is the backbone to 
support sustainable interventions. Community participation enhances the affordability of 
health interventions compared to conventional, vertical programmes, as recurrent costs 
become more affordable (Gish, 1992). In order to enhance community participation and 
engagement in the delivery of health services, many African countries have set up dialogue 
structures to facilitate communication between the health system and communities. These 
dialogue structures help bring promotion, prevention and cure together in a safe, effective, 
socially acceptable and productive way to the population. Its comprehensiveness, 
integration and continuity, make the dialogue structure a point of entry into the community 
to build an enduring relationship of trust between people, their health-care providers and 
the health system. Some of these structures have survived, but others have collapsed. Their 
poor conception and the exclusion of communities in their inception are some of the reasons 
of the failure. One of the cornerstones of PHC is working in partnerships. The partnerships 
that make the greatest impact in the rural population are those that are grounded at the 
community level. However, the mechanism for bringing together partners to improve their 
collaboration at this level remains problematic. The Community Directed Treatment with 
Ivermectin (CDTI), a process in which the community has the responsibility for the 
organization and delivery of treatment has been adopted by the African Programme for 
Onchocerciasis Control (APOC) as its strategy to control of onchocerciasis (Brieger et al., 
2002). CDTI promotes active community participation in decision making as a means of 
improving access to the drug, promoting a sense of responsibility and appropriation. It 
enhances ownership and empowerment of communities (Amazigo et al., 1998). CDTI is a 
stimulus for developing primary health care in areas with difficult access to formal health 
services (Hopkins, 1998; Richards et al., 2004). Field trials revealed the efficiency of 
communities to deliver multiple interventions of various degrees of complexity, thus 
strengthening the link between communities and the health system (WHO, 2008). 
Comprehensive revitalization of primary healthcare holds the potential to insure equity in 
access to health services. Community engagement and involvement in the planning, 
delivery and monitoring of health interventions, strengthens the interactions between health 
services and the communities and enhance needs-based and demand-driven provision of 
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services which in turn strengthens PHC delivery schemes (WHO, 2008). The lack of a legal 
framework and normative orientation also plague optimal community participation and 
stakeholders’ engagement. Community monitoring and referral of SAE cases is crucial in the 
management of onchocerciasis control programme in areas that are at risk of Loa loa 
mediated encephalopathy. 
4. Pathophysiology of Loa loa mediated encephalopathy 
Loa loa encephalopathy is related to the worm burden, especially the hypermicrofilaremia. 
Though its mechanism is not sufficiently understood, it is known that Ivermectine 
(Mectizan)®, in addition to being an effective drug against the microfilariae of Onchocerca 
volvulus (the causative agent of onchocerciasis), is also effective against L. loa microfilariae, 
the rapid killing of which has been associated with this encephalopathy. Encephalopathy 
may also be linked with higher permeability of brain capillaries as they react to a higher 
load of worm antigen released after massive destruction of Loa loa microfilaria in response to 
ivermectin administration. 
The obstruction of brain capillaries by paralyzed microfilariae lead to local ischemic 
reactions, increased pressure within the capillaries, rupture of the affected vessels and 
hemorrhagic suffusion. The hemorrhage equally occurs on the conjunctiva mucosa or on the 
palpebral area. The last manifestation has been used as a prognostic sign of encephalopathic 
involvement. 
5. Identification of individuals and communities at risk of encephalopathy 
5.1 Primary prevention of encephalopathy 
The reactions of Loa loa to onchocerciasis drugs date back from the use of Diethyl Carbamazine 
(DEC=Notezine) when severe adverse reactions with encephalopathy were reported. 
Ivermectin was known as a safe drug for the mass treatment of onchocerciasis until the 1999 
when several cases of SAEs occurred as distribution moved to the forest areas of Cameroon 
and Nigeria, that are breeding environments for Chrysops flies, the vectors of Loa loa. 
The high number of cases that occurred in Cameroon lead administrative authorities and 
APOC to stop distribution until clarifications were provided, the causes elucidated and 
preventive measures laid out. The World Health Organisation special programme for 
Research and Training in Tropical Diseases (TDR), together with a team of African scientist 
lead the development of RAPLOA, a rapid assessment method based on the history of 
migration of the adult Loa loa worm through the conjunctiva. Primary prevention equally 
makes use of community knowledge of Loa loa, which is an indicator of the level of 
endemicity. RAPLOA has been used to map the risk of Loa loa encephalopathy, in priority 
areas for onchocerciasis lymphatic filariasis within the framework of Neglected Tropical 
Diseases (NTD) control. (Figure 2) 
The delivery of RAPLOA entails the administration of a community and individual 
questionnaires. The RAPLOA community questionnaire helps in getting an onerall view the 
community experience and endemicity of Loa loa. Simple names for eye worm are often 
associated with high prevalence, while complex and composite names are associated to 
lower prevalences (Table 1). 
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Language / 
ethnic group 
Villages Vernacular name meaning 
(etymology) 
Baya Bedobo, Mbelibina, 
Bengue Tiko, Mbile, 
Belikoungou 
Yolo li 
 yolo=worm li=eye 
Worm of the eye 
Baya Mbelebina, Camp 
SODEPA, Bambouti, 
Garga Sarali, Ndanga 
Gadima, Dabole,  
Peng li  
peng=worm li=eye 
Worm of the eye 
Foulbe Camp SODEPA, 
Ndanga Gadima, 
Mbile, Belikoungou 
Guildé guité 
guildé=worm 
guité=eye 
Worm of the eye 
Kako Djal, Djassi Ntoro  Worm of the eye 
Kako Nyamsambo, Kamba 
Mieri, Ngoura, 
Ngoulmekong, Letta, 
Gbabele, Pouyanga, 
Gaba Letta, 
Kpangalakonga, Banda, 
Mbouye, Dem 2  
Kon missi  
kon=sickness  
missi=eye 
Eye sickness 
Maka Bouam, Baktala da 
biep 
Naki 
Worm of the eye 
Mbimou Mbiali Ntoli  worm of the eye 
Mezime Kagnol I, Bokendja, 
Kapang, Djampiel 
Djol Worm of the eye 
Mvongmvon Djemba Dol Worm of the eye 
Pol Grand Pol kon mich 
kon=worm 
mich=eye 
Worm of the eye 
Table 1. Vernacular names of eye worm in villages of Eastern Cameroon 
Several other conditions have been reported to favor encephalopathy in loasis areas and 
confound with the determinants of SAE. Among these are the consumption of alcoholic 
beverages, especially the traditional, non standard drinks that contain mixtures of alcohols, 
some of which may be neurotoxic such as methanol. 
Operational guidelines have been provided by the Technical Consultative Committee 
(TCC) of APOC on the implementation of ivermectin mass distribution in areas that are 
co-endemic for onchocerciasis and loiasis. Within this scheme, blanked treatment is not 
recommended and a distribution by axis is advocated based the capabilities of the human 
resources for health, infrastructure and logistic for the early detection, referral and 
management of cases. 
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Fig. 2. Relationship between the prevalence of very high microfilarial loads(>30.000 mf/ml) 
and RAP based on the history of eye worm (From TDR. Guidelines for the Rapid 
Assessment of Loa loa). 
 
Fig. 3. Delivery of the RAPLOA individual questionnaire to assess the risk of SAE at the 
community level, using the illustrated eye worm in Southern Sudan (Photo Dr Takougang) 
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5.2 Secondary prevention of encephalopathy 
Not all cases of SAE may be avoided through primary prevention. Thus, early identification 
and referral of cases of encephalopathy is of paramount importance. Early detection offers 
improved prognosis. In this regard, ataxia, sub-palpebral hemorrhage have been 
successfully used, two-three days after treatment, to identify and manage cases of SAEs 
which would have otherwise developed encephalopathy. 
Many lessons have been learned for improved clinical management of cases of 
encephalopathy in hospital settings. This has lead to improved survival and reduction in 
mortality among cases. 
 
 
Fig. 4. Sub-palpebral hemorrhage in a case of SAE in Cameroon (Photo Dr J. Kamgno). 
5.3 Tertiary prevention of encephalopathy 
The literature on the tertiary prevention of encephalopathy is scanty. Apart from clinical 
data that indicate measures to prevent bed sores, there is very little data on the disabilities 
that occur following SAE and encephalopathy. The sequelae and their impact on the 
patient’s productivity and quality of life needs to be assessed.  
6. Clinical and paraclinical features of Loa loa mediated encephalopathy 
Post onchocerciasis treatment encephalopathy occurs in people with very high levels of L. 
loa [> 30,000 microfilariae/milliliter blood (mf/ml)] following treatment with Mectizan®. 
The patient often presents with fever (39-40°C), head ache and ataxia. Signs of central 
nervous system involvement may follow. Such signs include confusion, omnibulation, 
lethargy, ataxia, anal and urinary incontinence. Unattented, the patient progresses into into 
coma. 
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7. Differential diagnosis 
Encephalopathy is a brain disease, damage or malfunction. Encephalopathy presents in a 
broad spectrum of symptoms that range from mild, such as memory loss or subtle 
personality changes to dementia, seizures, coma and death. Encaphalopathy on the early is 
often accompanied by physical manifestations such as poor coordination of limb 
movements (NINDS, 2011). 
A wide range of causes may lead to encephalopathy may be infectious (bacteria, viruses, 
parasites), anoxia (lack of oxygen to the brain), alcohol consumption, liver failure, kidney 
failure, metabolic diseases, brain tumors, toxic chemicals, alterations in pressure in the 
brain, and poor nutrition of nerve cells.  
Despite the numerous and varied causes of encephalopathy, an altered mental state is 
usually present. It may be subtle and develop slowly over years or rather rapidly (for 
example, brain anoxia leading to coma or death in a few minutes). Often, symptoms such as 
poor judgement or poor coordination of movements are reported. The severity and type of 
symptoms are related to the underlying cause. Alcohol-induced encephalopathy can result 
in involuntary hand tremors, while severe anoxia may result in coma with no movement. 
The diagnosis of encephalopathy is usually done by clinical tests done during the physical 
examination (mental status tests, memory tests, coordination tests) that document an altered 
mental state. Findings on clinical tests either diagnose or presumptively diagnose 
encephalopathy. Usually, a diagnosis is made when the altered mental state accompanies 
another primary condition such as chronic liver disease, kidney failure or anoxia.  
Many practitioners view encephalopathy as a complication that occurs following a primary 
underlying health problem. The frame work  for the diagnosis and management of cases of 
encephalopathy includes Complete blood count; search for underlying infections, 
assessment of blood pressure (high or low blood pressure); blood levels of electrolytes, 
glucose, lactate, ammonia, oxygen, and liver enzyme levels; drug use or toxin levels 
(alcohol, cocaine, amphetamines, ..); ceresbrospinal fluid analyses; kidney function 
(creatinine)  
Other diagnostic tools may be useful, but are not often present in Loa loa endemic settings. 
These include Computer Tomography (CT) and Magnetic Resonance Imaging (MRI) scans 
to assess brain swelling, anatomical abnormalities or infections; Doppler ultrasound to 
assess blood flow to tissues, encephalogram to assess brain wave patterns. 
In the case of Loa loa encephalopathies, microfilariae are sought in a standardized finger 
prick thick blood smear. The presence of such is indicative of the involvement of Loa loa in 
the genesis of encephalopathy. However, under the endemic conditions, infections agents 
such as Neisseria meningitidis, the cause of bacterial meningitis, Toxoplasma gondii, and 
malaria must be ruled out. Cerebral malaria is a likely co-factor in the occurrence of 
encephalopathy. Clinical orientation, experience, of the treating physician, the specific 
symptoms and history of the patient are of paramount importance in the early detection and 
management of cases. 
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8. Case reports 
Several cases of Loa loa encephalophathy occur each year in the DRC. During the 2009 
Mectizan distribution, the country reported the highest number in the history of 
participating in activities. Below are a selected number of cases to point out clinical 
presentation and management. 
Case Report #1 
Patient WB, aged 33 years old lived in the city of Abuzi in the Abuzi health Zone in the 
Equateur Province (The Democratic Republic of Congo). He swallowed 3 tablets of 
ivermectin on the 10/11/2009. He was 149 cm tall and weighed 52 kg. His general state was 
good before he swallowed ivermectin tablets. He had no history of alcohol consumption 24 
hours before or after ivermectin treatment. He presented with fever, altered behavior and 
coma on 11/11 2009, one day after he swallowed the tablets. He was transferred to the 
Abuzi reference hospital on the 12/11/2009 and was admitted on same day. At admission, 
the patient had urinary incontinence. His blood pressure and temperature were within the 
normal limits. Coma, stage 2 was diagnosed by the attending physician. 
Emmergency biomedical investigations revealed a microfilaremia of 2520 Loa loa mf/ml 
from of a thick blood film. The analysis of a concurrent thin blood smear revealed 
Plasmodium falciparum trophozoites.  
The diagnosis made by the attending physician was that of cerebral malaria with 
encephalopathy post ivermectin treatment. 
The treatment administered included:  
Intravenous drips of quinine in 5% glucose, Ringer lactate serum or physiological saline 
solutions.  
Antibiotics (Ampicilline, Direct intravenous injection) were equally administered was 
provided for bed sores as appropriate. 
Three days after admission, the patient developed bed sores that were unhealed on 
14/12/2009, when he was discharged. On discharge, the patient still experienced difficulties 
walking.  
Case report #2: 
Patient F., aged 28 years was from the village of Bukarawa , Loko Health Zone in the 
Equateur Province of the Democratic Republic of Congo. She was admitted in the Loko 
Health Zone Reference Hospital. At admission, the patient blood pressure was 180/120 
mmHg, the Glasgow score was estimated at 5 (coma stage 2) ; Temperature was 39°C.  
For her 146 cm height, the patient was reported to have taken 3 tablets of Mectizan 100g on 
06 December 2009. The general health status was good prior to the absorption of Mectizan 
tablets. On 06 December 2009, about 6 hours after absorption, the patient developed intense 
fever, altered behaviour and fainted. It was in this state that she was transferred to the 
reference hospital on 08 December 2009. Upon investigations with siblings the patient had 
not taken any alcoholic drink over the past 24 hours. On admission, the patient had bed 
sores on the lower part of the lower back, around the sacrum.  
www.intechopen.com
Encephalopathy Related to Ivermectin Treatment  
of Onchocerciasis in Loa loa Endemic Areas: Operational Considerations  
 
179 
The presumptive diagnosis was that of a Loa loa encephalopathy related to ivermectin, 
associated to cerebral malaria or meningitis.  
Biomedical evaluation of a thick blood film revealed Loa loa microfilariae (620 mf/ml). The 
glycemia was 186 mg/dl, that decreased to 111 mg/dl on the second day. White blood cell 
count was 9550/mm3, and the sedimentation coefficient (VS) 91 mm/h.  
The following treatment was administered: Intravenous administration of Quinine in 5% 
Glucose serum for 3 days. Glucose and Ringer Lactate were alternatively use as solutes. 
The anti-hypertensive drug Adalate 2X10mg was administered through a nasogastric 
gavage; Lasilix (Lasix) 40 mg was administered intravenously. 
The antipyretic drug Dipyrone was used in an intramuscular injection of 4X1g /day. 
For hyperleucocytopenia, an association of Ampicilline and Chloramphénicol was 
administred through direct intravenous injection 3X 1g /day. 
To alleviate bedsores, a nursing protocole for patient mobility was set. Topical antiseptics 
were used to cleanse the wound of the lower back.  
The treatment was followed for 5 days. However, the feverish state persisted, reaching 
40,5°C on day 5. Diastolic blood pressure went from 120 down to 100 mm Hg. The systolic 
Pressure decreased from 190 to 160 mmHg despite the treatment administered. 
The patient died on day 5. 
9. Management of cases of Loa loa mediated encephalopathy 
Like all life threatening conditions, Loa loa encephalopathy requires prompt medical and 
nursing care to provide supportive treatment and prevent nosocomial infections. With 
competent and timely medical care, patients usually recover.  
The main features of case management include the monitoring of vital signs, nutrition and 
nursing care.  
Vital signs of importance are blood pressure, pulse, body temperature and respiratory 
frequency. Nasogastric intubation may be useful in maintaining hydrolytic and nutrients 
intake for energy support.  
Rehydration using Ringer Lactate, physiological solution, hypertonic glucose may be used 
depending on the patient preexisting health status. Salt and glucose are to be monitored in 
hypertensive and diabetic patients. Nutrients intake should be shifted from parenteral to per 
os as soon as the patient is able to sustain feeding. In re-initiating autonomous feeding, 
preference is given to liquid diets including milk, soups enriched with soja or ground meat. 
Nursing care is of utmost importance for the prevention of bed sores that often results from 
hospital bed pressure. This is reduced through scheduled mobilization of the patient to 
release circulation and relieve pressure sites. The use of adequate mattresses and bed 
dressing may be helpful. Care also focuses on the liberation of airways as they are likely to 
obscure the prognosis. The detection and management of concurrent pathologies may 
improve the prognosis. This is especially the case for hypertension, diabetes, malaria, 
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meningitis and other health conditions. Malaria may be diagnosed incidentally in standard 
blood smears that are effected for the confirmatory diagnosis of Loa loa infection. It may 
equally be purposefully sought when there are signs such as fever, omnibulation, diarrhoea 
or other signs suggestive of simple or cerebral malaria. 
Practionners often recommend that corticoid should not be used as they may increase the 
risk of infection and/or gastrointestinal bleeding after prolonged use. 
Because SAE is a medical emergency, all laboratory support tasks should be performed 
steadily and timely. These include tests for glycemia, blood smears, analyses of cerebro-
spinal fluid for Loa loa parasites and concurrent infection, such as meningitis. 
10. Operational consideration of Loa loa interventions in onchocerciasis 
control 
APOC, the leading organization in onchocerciasis control in Africa has led the development 
of tools for early detection and management of cases of SAE. Todate, mortality associated 
with the occurrence of encephalopathy is on the decline. As ivermectine is effective against 
both Onchocerca and Loa loa, the occurrence of ESG is proportional to the prevalence of high 
Loa loa microfilaremic individuals in affected communities. Thus, the probability of having 
cases decreases with the duration of effective mass treatment cycles (Figure 5).  
 
Fig. 5. Evolution of SAE cases following Ivermectine (Mectizan) distribution in 
onchocerciasis and loiasis co-endemic areas in the Democratic Republic of Congo(2003-2009) 
Source : Technical Report 
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Even though the ESG represent a threat to CDTI operations, especially when 
encephalopathy triggered deaths are registered, it is still unethical to withhold treatment 
from thousands of people who live in oncherciasis and loiasis co-endemic areas. In that 
regard, special guidelines have been developed to inform mass distribution of ivermectine 
in such areas. Under such circumstances, operational teams are advised to avoid blanket 
treatment while giving precedence to focal, progressive treatment. The rate of expansion is 
then proportional to the number of expected cases of SAE, matched to the capacity of the 
local health infrastructure in available hospital beds, trained personnel and accessibility. 
Accessibility is a key determinant in countries where the road network is poor. Under some 
circumstances, mobile teams may be adopted or the capabilities of first line health facilities 
developed to permit the handling of severe illness resulting from SAE. 
11. Loa loa mediated encephalopathy and the future of neglected tropical 
diseases control 
Loiasis is a neglected disease that may have great social and economic impact in some 
endemic areas. Loiasis has for long been regarded as a benign filariasis. Its distribution that 
is limited to Central Africa has made it a less studied infection. The number of infected 
individuals was estimated at 2-13 millions (Fain, 1978). Interest in loiasis has been renewed 
as cases of encephalopathy occurred following treatment of onchocerciasis patients with 
high coincident Loa loa microfilareamia (Chippaux et al., 1996; Gardon et al., 1997; Twum-
Danso and Meredith, 2003). The occurrence of SAE affects compliance, treatment coverage 
and the sustainability of CDTI (Amazigo et al., 1998). Data on the distribution of Loa loa 
infection became mandatory to assess the risk of severe adverse events (SAE) as community 
directed treatment of onchocerciasis with ivermectin (CDTI) was extended to loiasis 
endemic areas. SAE are a constraint to community participation and compliance with CDTI. 
Working in Cameroon, the prevalence of Loa loa microfilareamia was found to reach rate of 
31.5% in adults living in the dense forest area of Yokadouma (Languillon, 1957). Prevalences 
ranging from 9.6% to 13.5% were reported in the population of Colomines in the savannah 
area of the Kadei valley (Haumont et al., 1992). A model using satellite mapping of key 
environmental factors related to the biology of the Chrysops vector predicts a high 
prevalence of Loa loa at the regional level (Thomson et al., 2004), but the endemicity of loiasis 
at the community level may be unexpected (Kamgno and Boussinesq, 2001., Wanji et al., 
2001). A study in eastern Cameroon indicated a high morbidity of the disease (Takougang et 
al., 2002). Loiasis was the second or third cause of medical consultations after malaria and 
pulmonary diseases in some endemic regions (Boulesteix and Carme, 1986; Pinder, 1988). 
Clinical manifestations of loasis in endemic areas have received little attention (Agbolade et 
al., 2005). The subconjunctival migration of adult worm, migratory angioedema and pruritus 
were the most reported signs (Carme et al, 1989; Noireau et al., 1990).   
In most areas, the prevalence of eye worm and Calabar swellings were higher than that of 
microfilareamia. These observations denote that most clinical cases of Loa loa filariasis are 
amicrofilaraemic, and confirm previous observations (Touré et al., 1998; Touré et al., 1999, 
Pion et al., 2005). The prevalence of Loa loa infection that is estimated through the 
microscopic examination of standard blood film thus leads to an underestimation of the 
prevalence of loiasis. RAPLOA (Takougang et al., 2002), a tool based on the history of eye 
worm that is used for the rapid assessment of Loa loa infection, may provide a better 
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estimate of the affliction. The term used for the identification of eye worm disease was 
consistent among the ethnic groups and languages. Most of the local names were composite, 
derived from the terms for “worm” and “eye”. The widespread knowledge of signs and 
symptoms of Loa loa infection are an asset for community involvement in control, health 
education and promotion activities (Hewlett et al., 1996). The local names for Calabar 
swellings were less consistent than those of eye worm. Reports of Calabar swellings with 
intense itching corroborate previous findings (Morrone et al., 2002). The itching that is 
associated with Calabar swellings can be a cause of distraction from economic activities, and 
a source of social stigma and low self-esteem (Noireau, 1989). Subconjunctival migration of 
the worm causes considerable discomfort. It was associated with arthralgia and fatigue 
(Pinder, 1988; Morrone et al., 2002). These are constrains to productivity and economic 
development. The morbidity of eye worm disease may be heightened by the reported 
practices of traditional removal of the worm using a sharp blade, drops from the plants 
Allium cepa or Tithonia diversifolia, all of which may further damage the afflicted eye. The risk 
of physical and chemical damages to the eye consecutive to the local treatment practices, the 
secondary bacterial infections associated with local treatments may add on to the morbidity 
of loiasis in endemic populations. Loa loa related hypereosinophilia was suspected of 
playing a role in the aetiology of endocardial fibrosis (Pinder, 1988). In some case histories, 
glomerulonephritis, cardiomyopathy, retinopathy, lymphadenitis and lymphodoema were 
reported (Morrone et al., 2002; Agbodale et al., 2005). In a study carried out in Congo, 
headache and arthralgia were associated with Loa loa infection (Carme et al., 1989). The risk 
of SAE that has motivated most recent studies on Loa loa may therefore be a limited view of 
its health risks spectrum. There is an urgent need of interventions to prevent its health 
consequences. In that regard, albendazole may be a useful tool (Tabi et al., 2004). The mass 
distribution of ivermectin and albendazole within CDTI projects within the Global 
Programme to Eliminate Lymphatic Filariasis (GPELF) will have an incidental impact on Loa 
loa infection (Chippaux et al., 1998; Tsague-Dongmo, 2002).  
Field observations have pointed out the effect of alcohol as a co-factor in the determination 
of ivermectin mediated SAE, but the information available is conflictive. Food and alcohol 
are known to alter ivermectin bio-availability (Baraka et al., 1996). The contra-indication of 
alcohol consumption around Ivermectine (Mectizan) intake as indicated by Merck & Co., 
Inc. have safety concerns, but may unnecessarily deter some people from taking ivermectin 
(The Mectizan Expert Committee, 2000). Shu et al. (2000) failed to establish any enhanced 
occurrence of side effects in patients who consumed alcohol. .In a study carried out in 
Cameroon where some local beverages are produced from uncontrolled fermentation, with 
obviously higher alcohol content and diversity, Takougang et al. (2006) reported that the risk 
of SAE was higher when Ivermectine (Mectizan) was taken for the first time. Males were 
more likely than females to develop SAE. The occurrence of SAE was not associated with 
the timing of the last alcohol consumption, indicating that alcohol intake is not a major 
determinant of SAE. Because of the limited number of cases, the authors did not separate the 
different types of alcohols consumed. High content distilled alcohols may contribute to SAE, 
as these beverages contain a variety of alcohols which may be neurotoxic. Still the local palm 
and raphia wines, are blended with plant adjuvants, some of which may be potent 
neurotoxics. The plant Paullina pinnata (Salpindaceae) – locally called ‘Mbami’, ‘Mbarbi’ or 
‘lianes’ – is known to cause head ache. The influence of these adjuvants as determinants of 
SAE deserves further investigations.  
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It is possible that some participants (cases) could have denied alcohol consumption for fear 
of loosing the coverage of hospital costs as practiced by the National Onchocerciasis Control 
Programme.  
One of the determinants of alcohol use and abuse contribution to ill health is the type of 
alcoholic beverage. Ethanol that is found in beverages may not be a key factor in SAE (Shu et 
al., 2000), but other alcohols such as methanol or buthanol of the locally produced “Arki”, 
“Odontol” or “Hah” could contribute. The plant adjuvants of beverages may be at least co-
factors. In one instance, a community distributor reported that a patient who developed 
SAE had ingested palm wine after ivermectin treatment. A similar case was quoted by 
Boussinesq et al. (2003). While there is an increased bioavailability of ivermectin following 
its co-administration with ethanol (Edwards et al., 1988; Cerkvenik and Grabnar, 2002), it is 
unlikely that the level of Ivermectin reached is high enough to cause SAE. The adjuvants of 
palm wine reported by Takougang et al., 2006 contain tannins, alkaloids and saponins 
which are all potent on the nervous system. Tannins increase capillary resistance, reduce 
capillary permeability of the red blood cells and are vasoconstrictors. Vasoconstriction of the 
extracranial arteries causes headache, restlessness and dizziness. Saponins are characterised 
by their tensio-active properties. Many saponins speed up haemoglobin degradation 
through their interaction with sterols of the membrane of the red blood cells. Alkaloids are 
complex nitrogenous substances with a bitter taste, that which is most preferred by 
consumers of palm wine. Alkaloids can be stimulants or depressors of the central nervous 
system (Bruneton, 1999). It is therefore required that the role of plant used as adjuvants in 
alcoholic drinks, as co-factors in SAE should be further assessed. 
12. Conclusion 
Early detection, operational adjustment and research based decision-making has 
contributed to improved management of SAE and encephalopathy in the control of 
onchocerciasis. However, further investigations are warranted on the sequelae and impact 
of encephalopathies on patient’s productivity and quality of life. As the implementation of 
integrated control of Neglected Tropical Diseases progresses outside the onchocerciasis 
endemic areas, more challenges will be faced in lymphatic filariasis elimination areas. 
Implementation research will be needed to address operational issues, compliance, detection 
of novel side effects resulting from the co-administration of ivermectin, Albendazole and 
Praziquantel in previously naïve areas. Scaling up these interventions will equally face the 
genetic variability of human hosts and their cultural and behavioral correlates. 
Multidisciplinary collaborative research including epidemiology, social science, clinical and 
biological sciences will be warranted to address these issues. 
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